Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada

Current Drug Abuse Reviews

Volumn 6, Issue 1, 2013, Pages 30-42

  Thomas, Gerald ^a   Lucas, Philippe ^a   Capler, N Rielle ^b   Tupper, Kenneth W ^b   Martin, Gina ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Addiction; Ayahuasca; Cocaine; Harm reduction; Substance dependence; Substance use

Indexed keywords

AYAHUASCA; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ABORIGINE; ADDICTION; ADULT; ALCOHOLISM; ARTICLE; BEHAVIOR CHANGE; CANADA; CANNABIS ADDICTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; DRUG EFFECT; EMPOWERMENT; FEMALE; FOLLOW UP; HARM REDUCTION; HUMAN; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RURAL AREA; SELF REPORT; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BANISTERIOPSIS; CANADA; COUNSELING; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; QUESTIONNAIRES; RURAL POPULATION; SUBSTANCE-RELATED DISORDERS;

EID: 84880161842     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/15733998113099990003     Document Type: Article

References (71)

1. Shanon B. The antipodes of the mind: Charting the phenomenology of the ayahuasca experience. Oxford: Oxford University Press; 2002.
2. Riba J, Rodriguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology 2001; 154: 85-95.
3. Brierley DI, Davidson C. Developments in harmine pharmacology - implications for ayahuasca use and drug-dependence treatment. Prog Neuropsychopharmacol Biological Psychiatry 2012; 39(3): 263-72.
4. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacol Therapeut 2004; 102(2): 111-29.
5. Beyer SV. Singing to the plants: A guide to mestizo shamanism in the upper Amazon. Albuquerque, NM: University of New Mexico Press; 2009.
6. Labate BC, Jungaberle H, editors. The internationalization of ayahuasca. Zürich: Lit Verlag; 2011.
7. Tupper KW. The globalization of ayahuasca: Harm reduction or benefit maximization? Int J Drug Policy 2008; 19(4): 297-303.
8. Barbosa PCR, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Testing Analysis 2012; 4(7- 8): 601-9.
9. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nervous Mental Disease 1996; 184(2): 86-94.
10. Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monitor 2008; 14(8): SR15-SR22.
11. Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz APM. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol 2007; 112(3): 507-13.
12. Doering-Silveira E, Lopez E, Grob CS, et al. Ayahuasca in adolescence: A neuropsychological assessment. J Psychoactive Drugs 2005; 37(2): 123-8.
13. Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Dependence 2010; 111(3): 257-61.
14. Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 2007; 102(1): 24-34.
15. Mabit J. Ayahuasca in the treatment of addictions. In: Winkelman MJ, Roberts TB, editors. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport, CT: Praeger Publishers; 2007. p. 87-105.
16. Labate BC, Santos RGd, Anderson B, Mercante M, Barbosa PCR. The treatment and handling of substance dependence with ayahuasca: Reflections on current and future research. In: Labate BC, MacRae E, editors. Ayahuasca, ritual and religion in Brazil. London: Equinox Publishing; 2010. p 205-27.
17. Liester MB, Prickett JI. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J Psychoactive Drugs 2012; 44(3): 200-8.
18. Bogenschutz MP, Pommy JM. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Testing Analysis 2012; 4(7- 8): 543-55.
19. Health Canada. A statistical profile on the health of First Nations in Canada: Determinants of health, 1999 to 2003. Ottawa: Health Canada, First Nations and Inuit Health Branch; 2009.
20. MacMillan HL, MacMillan AB, Offord DR, Dingle JL. Aboriginal health. Canadian Med Assoc J 1996; 155(11): 1569-78.
21. Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 2003; 98(3): 291-303.
22. Maté G. In the realm of hungry ghosts: Close encounters with addiction. Toronto: Vintage Canada; 2008.
23. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behavioral Assessment 2004; 26(1): 41-54.
24. Jones BT, Corbin W, Fromme K. A review of expectancy theory and alcohol consumption. Addiction 2002; 96(1): 57-72.
25. Werner K, Gross JJ. Emotional regulation and expectancy theory: A conceptual framework. In: Kring AM, Sloan DM, editors. Emotional regulation and psychopathology: A transdiagnostic approach to etiology and treatment. New York: Guilford Press; 2010. p. 13-37.
26. Murphy A, Taylor E, Elliott R. The detrimental effects of emotional process dysregulation on decision-making in substance dependence. Frontiers Integrative Neurosci 2012; 6(101): 1-24.
27. Azizi A, Borjali A, Golzari M. The effectiveness of emotion regulation training and cognitive therapy on the emotional and addictional problems of substance abusers. Iranian J Psychiatry 2010; 5(2): 60-5.
28. Kun B, Demetrovics Z. Emotional intelligence and addictions: A statistic review. Substance Use Misuse 2010; 45(7-8): 1131-60.
29. Cardaciotto L, Herbert JD, Forman EM, Moitra E, Farrow V. The assessment of present-moment awareness and acceptance: The Philadelphia Mindfulness Scale. Assessment 2008; 15(2): 204-23.
30. Hoppes K. The application of mindfulness-based cognitive interventions in the treatment of co-occurring addictive and mood disorders. CNS Spectrums 2006; 11(11): 829-51.
31. Greeson JM. Mindfulness research update: 2008. J Evidence-Based Complimentary Alternative Med 2008; 14(1): 10-8.
32. Skanavi S, Laqueille X, Aubin HJ. Mindfulness based interventions for addictive disorders: A review. Encephale 2011; 37(5): 379-87.
33. Bowen S, Chawla N, Collins SE, et al. Mindfulness-based relapse prevention for substance use disorders: A pilot efficacy trial. Substance Abuse 2009; 30(4): 295-305.
34. Miller JJ, Fletcher K, Kabat-Zinn J. Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. General Hospital Psychiatry 1995; 17(3): 192-200.
35. Strosahl KD, Hayes SC, Bergan J, Romano P. Assessing the field effectiveness of acceptance and commitment therapy: An example of the manipulated training research method. Behavior Therap 1998; 29(1): 35-63.
36. Robins CJ, Chapman AL. Dialectical behavior therapy: Current status, recent developments, and future directions. J Personality Disorders 2004; 18(1): 73-89.
37. Sipe WE, Eisendrath SJ. Mindfulness-based cognitive therapy: theory and practice. Canadian J Psychiatry 2012; 57(2): 63-9.
38. Rogers ES, Chamberlin J, Ellison ML, Crean T. A consumerconstructed scale to measure empowerment among users of mental health services. Psychiatric Services 1997; 48(8): 1042-7.
39. Wallerstein N, Bernstein E. Empowerment education: Freire's ideas adapted to health education. Health Edu Behavior 1988; 15(4): 379-94.
40. Fallot RD, Harris M. The Trauma Recovery and Empowerment Model (TREM): Conceptual and practical issues in a group intervention for women. Community Mental Health J 2002; 38(6): 475-85.
41. Berg M, Coman E, Schensul JJ. Youth action research for prevention: A multi-level intervention designed to increase efficacy and empowerment among urban youth. Am J Community Psychol 2009; 43(3-4): 345-59.
42. Aguilera S, Plasencia AV. Culturally appropriate HIV/AIDS and substance abuse prevention programs for urban native youth. J Psychoactive Drugs 2005; 37(3): 299-304.
43. Fallot RD, Harris M. Integrated trauma services teams for women survivors with alcohol and other drug problems and co-occurring mental disorders. Alcoholism Treatment Quarterly 2004; 22(3-4): 181-99.
44. Blume AW, Lovato LV. Empowering the disempowered: Harm reduction with racial/ethnic minority clients. J Clin Psychol 2009; 66(2): 189-200.
45. Harris M. Trauma recovery and empowerment: A clinician's guide for working with women in groups. New York: Free Press; 1998.
46. Rush B, Urbanoski K, Bassani D, et al. Prevalence of co-occurring substance use and other mental disorders in the Canadian population. Canadian J Psychiatry 2008; 53(12): 800-9.
47. Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The substance use risk profile scale: A scale measuring traits linked to reinforcementspecific substance use profiles. Addictive Behaviors 2009; 34(12): 1042-55.
48. Clarke PB. The relationship between wellness, emotion regulation, and relapse in adult outpatient substance abuse clients [Ph.D. dissertation]. Greensboro, NC: University of North Carolina; 2012.
49. Marlatt G, Gordon J. Determinants of relapse: Implications for the maintenance of behavior change. In: Davidson PO, Davidson SM, editors. Behavioral medicine: Changing health lifestyles. New York: Brunner/Mazel; 1980. p. 410-52.
50. Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: A multi-centre Canadian study demonstrating the importance of the existential domain Palliative Medicine 1997; 11(3): 3-20.
51. Shanon B. The epistemics of ayahuasca visions. Phenomenol Cognitive Sci 2010; 9(2): 263-80.
52. World Health Organization. The ASSIST project - Alcohol, smoking and substance involvement screening test 2010 [updated 2010; cited]; Available from: http://www.who.int/substance_abuse/activities/assist/en/index.html.
53. Adlaf EM, Begin P, Sawka E, editors. Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms-detailed report. Ottawa: Canadian Centre on Substance Abuse; 2005.
54. Humeniuk R, Ali R, Babor TF, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction 2008; 103(6): 1039-47.
55. Field A. Discovering statistics using SPSS. 2nd ed. London: Sage Publishing; 2005.
56. Jilek WG. Indian healing: Shamanic ceremonialism in the Pacific Northwest. Surrey, BC: Hancock House; 1982.
57. Fotiou E. Working with "la medicina": Elements of healing in contemporary ayahuasca rituals. Anthropol Consciousness 2012; 23(1): 6-27.
58. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994; 13(1): 39-46.
59. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG. Psychological and cognitive effects of long-term peyote use among Native Americans. Biological Psychiatry 2005; 58(8): 624-31.
60. Albaugh BJ, Anderson PO. Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry 1974; 131(11): 1247-50.
61. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006; 187(3): 268-83.
62. Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008; 22(6): 621-32.
63. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26(7): 994-1002.
64. Winkelman MJ, Roberts TB, editors. Psychedelic medicine: New evidence for hallucinogenic substances as treatments. Westport, CT: Praeger Publishers; 2007.
65. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25(11): 1453-61.
66. Callaway JC. Various alkaloid profiles in decoctions of Banisteriopsis caapi. J Psychoactive Drugs 2005; 37(2): 151-5.
67. Callaway JC, Brito GS, Neves ES. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. J Psychoactive Drugs 2005; 37(2): 145-50.
68. Tupper KW. Ayahuasca, entheogenic education & public policy [Ph.D. dissertation]. Vancouver: University of British Columbia; 2011. Available from: http://www.kentupper.com/resources/Ayahuasca+Entheogenic+Ed uc+$26+Public+Policy+-+Tupper+2011.pdf
69. Office of Controlled Substances. Exemption under Section 56 of the Controlled Drugs and Substances Act (Public Interest) Regarding the Use of Daime Tea for Religious Purposes. Ottawa: Health Canada; February 2008; Available from: http://www.bialabate.net/wpcontent/uploads/2008/08/Santo_Daime_Exemption_Health_Canada_IAS_2008.pdf
70. Posner M. B.C. doctor agrees to stop using Amazonian plant to treat addictions. November 9, 2011; Available from: http://www.theglobeandmail.com/life/health/new-health/healthnews/bc-doctor-agrees-to-stop-using-amazonian-plant-to-treataddictions/article2231413/.
71. Aglukkaq L. Letter to Dr. J. Rochester. Ottawa; October 23, 2012; Available from: http://www.bialabate.net/wpcontent/uploads/2008/08/CeudoMontreal_HC-Response-Letter-23-Oct-2012-2.pdf